FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168533476> ?p ?o ?g. }

• W3168533476 endingPage "e18824" @default.
• W3168533476 startingPage "e18824" @default.
• W3168533476 abstract "e18824 Background: Recent advances in NGS testing have revolutionized the scope for personalized medicine. The goal of this study was to describe historic trends in the average allowed cost for NGS testing. Methods: This was a retrospective database study evaluating biomarker testing claims in patients undergoing tumor and/or germline sequencing tests between 2016-2019. Molecular testing claims data and marketplace data of tests currently sold in the U.S. were analyzed in the proprietary Concert Genetics Medical Claims Data Warehouse. Results: Analysis of data highlighted high variability in utilization rates as well as allowed amounts for NGS testing. The average allowed amounts for NGS Tests varied from $1269 to $2058 per test during the study period. Higher variability in billing codes and price was also observed when analysis was done for subgroups, which included region, age, gender and cancer type. Similar trends were also observed for panels containing NGS-derived tests such as Tumor Mutation Burden (TMB), an upcoming biomarker. Average allowed amounts for NGS tests that included TMB testing varied from $438 to $3700 per test. To gain a better perspective on evolution of coding, utilization and pricing trends, additional analyses were done in hereditary cancer, given longer availability of these tests in the US Market. For Hereditary cancers, the average allowed amounts varied from $1722 to $2249 per test during the study period. Greater consistency in price was observed in hereditary cancer. Utilization is also more consistent over time and price showed a gradual decreasing trend over time. Coding was also less variable per claim for hereditary cancer and showed a converging trend. Conclusions: Understanding and quantifying the trends in cost of NGS testing for novel biomarkers is critical to predict evolution of testing costs and provide insights essential for minimizing barriers to availability and affordability of these tests. NGS testing can play an important role in improving quality of care and making the clinical decision-making process more efficient. Currently, coverage and reimbursement of NGS tests is one of the key policy challenges that needs to be addressed. Hence, development and adoption of policies is needed to ensure efficient integration of NGS testing in the US health care system." @default.
• W3168533476 created "2021-06-22" @default.
• W3168533476 creator A5007542966 @default.
• W3168533476 creator A5010277979 @default.
• W3168533476 creator A5027472331 @default.
• W3168533476 creator A5043157473 @default.
• W3168533476 creator A5068436236 @default.
• W3168533476 creator A5075781740 @default.
• W3168533476 date "2021-05-20" @default.
• W3168533476 modified "2023-09-30" @default.
• W3168533476 title "Real-world trends in costs of next generation sequencing (NGS) testing in U.S. setting." @default.
• W3168533476 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e18824" @default.
• W3168533476 hasPublicationYear "2021" @default.
• W3168533476 type Work @default.
• W3168533476 sameAs 3168533476 @default.
• W3168533476 citedByCount "7" @default.
• W3168533476 countsByYear W31685334762022 @default.
• W3168533476 countsByYear W31685334762023 @default.
• W3168533476 crossrefType "journal-article" @default.
• W3168533476 hasAuthorship W3168533476A5007542966 @default.
• W3168533476 hasAuthorship W3168533476A5010277979 @default.
• W3168533476 hasAuthorship W3168533476A5027472331 @default.
• W3168533476 hasAuthorship W3168533476A5043157473 @default.
• W3168533476 hasAuthorship W3168533476A5068436236 @default.
• W3168533476 hasAuthorship W3168533476A5075781740 @default.
• W3168533476 hasConcept C121608353 @default.
• W3168533476 hasConcept C126322002 @default.
• W3168533476 hasConcept C143998085 @default.
• W3168533476 hasConcept C2780673598 @default.
• W3168533476 hasConcept C32220436 @default.
• W3168533476 hasConcept C60644358 @default.
• W3168533476 hasConcept C71924100 @default.
• W3168533476 hasConcept C86803240 @default.
• W3168533476 hasConceptScore W3168533476C121608353 @default.
• W3168533476 hasConceptScore W3168533476C126322002 @default.
• W3168533476 hasConceptScore W3168533476C143998085 @default.
• W3168533476 hasConceptScore W3168533476C2780673598 @default.
• W3168533476 hasConceptScore W3168533476C32220436 @default.
• W3168533476 hasConceptScore W3168533476C60644358 @default.
• W3168533476 hasConceptScore W3168533476C71924100 @default.
• W3168533476 hasConceptScore W3168533476C86803240 @default.
• W3168533476 hasIssue "15_suppl" @default.
• W3168533476 hasLocation W31685334761 @default.
• W3168533476 hasOpenAccess W3168533476 @default.
• W3168533476 hasPrimaryLocation W31685334761 @default.
• W3168533476 hasRelatedWork W2025802152 @default.
• W3168533476 hasRelatedWork W2053050643 @default.
• W3168533476 hasRelatedWork W2061277785 @default.
• W3168533476 hasRelatedWork W2084274906 @default.
• W3168533476 hasRelatedWork W2106909021 @default.
• W3168533476 hasRelatedWork W2410844646 @default.
• W3168533476 hasRelatedWork W2983979507 @default.
• W3168533476 hasRelatedWork W4205528533 @default.
• W3168533476 hasRelatedWork W4205994479 @default.
• W3168533476 hasRelatedWork W2183326712 @default.
• W3168533476 hasVolume "39" @default.
• W3168533476 isParatext "false" @default.
• W3168533476 isRetracted "false" @default.
• W3168533476 magId "3168533476" @default.
• W3168533476 workType "article" @default.